

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE FOURTH QUARTER ENDED 31 JULY 2023<sup>(1)</sup>**

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	31.7.2023	31.7.2022	31.7.2023	31.7.2022
	RM'000	RM'000	RM'000	RM'000
Revenue	12,015	7,411	45,432	50,738
Cost of sales	(6,312)	(4,672)	(26,499)	(32,079)
Gross profit	5,703	2,739	18,933	18,659
Other income	537	266	1,926	657
Marketing expenses	(164)	(126)	(700)	(648)
Administrative and other expenses	(1,532)	(2,401)	(6,974)	(9,379)
Finance costs	(45)	(174)	(253)	(807)
Profit before tax	4,499	304	12,932	8,482
Taxation	(1,092)	264	(2,568)	(2,056)
Profit for the financial period/year	3,407	568	10,364	6,426
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income	3,407	568	10,364	6,426
Profit attributable to:				
Owners of the parent	3,371	568	10,316	6,426
Non-controlling interests	36	-	48	-
	3,407	568	10,364	6,426
Earnings per share attributable to owners of the parent ("EPS"):				
Basic and diluted <sup>(2)</sup> (sen)	0.90	0.15	2.76	1.72

**Notes:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2022 and the accompanying explanatory notes attached to this interim financial report.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period/year under review.

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2023<sup>(1)</sup>**

	Unaudited as at 31 July 2023 RM'000	Audited as at 31 July 2022 RM'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	24,370	21,009
Right-of-use assets	4,810	4,900
Deferred tax assets	-	432
Goodwill <sup>(2)</sup>	287	-
<b>Current assets</b>		
Inventories	12,514	9,460
Trade and other receivables	12,799	7,359
Marketable securities	11,874	21,007
Current tax assets	568	562
Derivative assets	6	-
Cash and bank balances	6,107	4,160
<b>TOTAL ASSETS</b>	<b>73,335</b>	<b>68,889</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Share capital	44,348	44,348
Reserves	18,647	8,331
Equity attributable to owners of the parent	62,995	52,679
Non-controlling interest	482	-
<b>TOTAL EQUITY</b>	<b>63,477</b>	<b>52,679</b>
<b>Non-current liabilities</b>		
Borrowings	2,877	5,584
Lease liabilities	7	15
Government grants	2,873	3,243
Deferred tax liabilities	307	4
<b>Current liabilities</b>		
Trade and other payables	2,583	4,052
Borrowings	711	2,412
Lease liabilities	44	40
Government grants	370	370
Current tax liabilities	86	490
<b>TOTAL LIABILITIES</b>	<b>9,858</b>	<b>16,210</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>73,335</b>	<b>68,889</b>

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2023<sup>(1)</sup> (cont'd)**

**Notes:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Financial Position is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2022 and the accompanying explanatory notes attached to this interim financial report.
- (2) UMediC Group Berhad ("**UMC**" or the "Company") on 30 March 2023 completed the acquisition of 280,000 ordinary shares in Patho Solutions (M) Sdn Bhd ("**Patho**"), representing 70% equity interest in Patho, for a cash consideration of RM600,000 ("**Acquisition**"). On 31 March 2023, UMC subscribed an additional 700,000 new ordinary shares in Patho at an issue price of RM1.00 per share, for a cash consideration of RM700,000 ("**Subscription**").

Upon completion of the Acquisition and the Subscription, Patho is now a 70%-owned subsidiary of UMC.

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FOURTH QUARTER ENDED 31 JULY 2023<sup>(1)</sup>**

	Attributable to owners of the Parent					
	Non-distributable		Distributable		Non-controlling interest	Total equity
	Share capital	Reorganisati on debit reserve	Retained earnings	Total		
RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	
Balance as at 1 August 2022	44,348	(6,851)	15,182	52,679	-	52,679
Profit for the financial year	-	-	10,316	10,316	48	10,364
Other comprehensive income, net of tax	-	-	-	-	-	-
Total comprehensive income	-	-	10,316	10,316	48	10,364
<u>Transactions with owners</u>						
- Acquisition of subsidiary in business combination under common control	-	-	-	-	134	134
- Ordinary shares	-	-	-	-	300	300
Total transactions with owners	-	-	-	-	434	434
<b>Balance as at 31 July 2023</b>	<b>44,348</b>	<b>(6,851)</b>	<b>25,498</b>	<b>62,995</b>	<b>482</b>	<b>63,477</b>

**Note:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Changes in Equity is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2022 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE FOURTH QUARTER ENDED  
31 JULY 2023<sup>(1)</sup>**

	12-month ended 31 July 2023 RM'000	12-month ended 31 July 2022 RM'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before tax	12,932	8,482
Adjustments for:		
Depreciation of property, plant and equipment	2,048	1,529
Depreciation of right-of-use assets	138	218
Amortisation of government grants	(370)	(87)
Fair value adjustment on derivative assets	(6)	-
Finance costs	253	807
Gain on disposal of property, plant and equipment	-	(2)
Gain on lease terminations <sup>(2)</sup>	*	*
Interest income	(108)	(116)
Distribution income from short-term fund	(303)	(1)
Property, plant and equipment written off	2	-
Realised gain on fair value adjustment on marketable securities	(268)	(6)
Reversal of impairment losses on trade receivables	(12)	(14)
Unrealised loss/(gain) on foreign exchange	142	(9)
Operating profit before changes in working capital	14,448	10,801
(Increase)/Decrease in inventories	(2,693)	656
(Increase)/Decrease in trade and other receivables	(5,357)	2,743
Decrease in trade and other payables	(2,449)	(3,173)
Cash generated from operations	3,949	11,027
Interest received	108	117
Tax paid	(2,677)	(2,665)
Tax refunded	424	-
<b>Net cash from operating activities</b>	<b>1,804</b>	<b>8,479</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Acquisition of subsidiary, net of cash acquired <sup>(3)</sup>	287	-
Purchase of marketable securities	(25,800)	(21,000)
Purchase of property, plant and equipment	(5,313)	(1,011)
Proceeds from disposal of marketable securities	35,504	-
Proceeds from disposal of property, plant and equipment	-	32
<b>Net cash from/(used in) investing activities</b>	<b>4,678</b>	<b>(21,979)</b>

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE FOURTH QUARTER ENDED 31 JULY 2023<sup>(1)</sup> (Cont'd)**

	12-month ended 31 July 2023	12-month ended 31 July 2022
	RM'000	RM'000
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Capital contribution of non-controlling interest	300	-
Drawdown of bankers' acceptance	6,100	1,450
Repayment of bankers' acceptance	(7,550)	(9,450)
Drawdown of term loans	-	597
Repayment of term loans	(2,958)	(9,790)
Interest paid	(251)	(743)
Payment of lease liabilities	(55)	(1,217)
Proceeds from issuance of shares	-	30,514
Government grant received	-	3,549
<b>Net cash (used in)/from financing activities</b>	<b>(4,414)</b>	<b>14,910</b>
Net increase in cash and cash equivalents	2,068	1,410
Effect of foreign exchange rates changes	(120)	(11)
Cash and cash equivalents at beginning of financial years	4,160	2,761
Cash and cash equivalents at end of financial years	6,108	4,160

**Notes:**

\* Represent less than RM1,000.

- (1) The basis of preparation of the Unaudited Consolidated Statement of Cash Flows is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2022 and the accompanying explanatory notes attached to this interim financial report.
- (2) There is a gain on lease terminations amounting to RM251 during the current financial year and RM368 for financial year ended 31 July 2022.
- (3) The recognised amounts of assets acquired and liabilities assumed at the date of acquisition were:

	Pre-acquisition carrying amount RM'000
Property, plant and equipment	99
Right-of-use assets	59
Inventories	361
Trade and other receivables	93
Cash and cash equivalents	887
Deferred tax assets <sup>(a)</sup>	*
Lease liability	(60)
Trade and other payables	(982)
Current tax liabilities	(10)
<b>Total identifiable net assets</b>	<b>447</b>
	<b>RM'000</b>
Purchase consideration settled in cash and cash equivalents	600
Cash and cash equivalents	(887)
<b>Net cash inflow on acquisition</b>	<b>(287)</b>

**Note:**

- (a) There is deferred tax assets amounting to RM127.

## A. NOTES TO THE INTERIM FINANCIAL REPORT

### A1. Basis of preparation

The interim financial report of UMediC Group Berhad (“**UMC**” or the “**Company**”) and its subsidiaries (collectively, the “**Group**”) is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (“**MFRS**”) 134, Interim Financial Reporting issued by the Malaysian Accounting Standards Board (“**MASB**”) and Rule 9.22 of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”) (“**Listing Requirements**”).

This interim financial report should be read in conjunction with the Group’s Audited Financial Statements for the financial year ended 31 July 2022 and the accompanying explanatory notes attached to this interim financial report.

### A2. Significant Accounting Policies

The significant accounting policies and methods of computation applied in the unaudited condensed financial statements are consistent with those adopted in audited financial statements for the financial year ended 31 July 2022, except for the adoption of the following MFRSs and Amendment to MFRSs and Interpretation.

#### (a) New MFRSs adopted during the financial year

The Group and the Company adopted the following Standards of the MFRS Framework that were issued by the MASB during the financial periods:

Title	Effective Date
Annual Improvements to MFRS Standards 2018 - 2020	1 January 2022
Amendments to MFRS 3 <i>Reference to the Conceptual Framework</i>	1 January 2022
Amendments to MFRS 116 <i>Property, Plant and Equipment – Proceeds before Intended Use</i>	1 January 2022
Amendments to MFRS 137 <i>Onerous Contract - Cost of Fulfilling a Contract</i>	1 January 2022

Adoption of the above Amendments to Standards did not have any material effect on the financial performance or position of the Group and of the Company.

#### (b) New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2023

Title	Effective Date
MFRS 17 <i>Insurance Contracts</i>	1 January 2023
Amendment to MFRS 17 <i>Initial Application of MFRS 17 and MFRS 9 - Comparative Information</i>	1 January 2023
Amendments to MFRS 101 <i>Disclosure of Accounting Policies</i>	1 January 2023
Amendments to MFRS 108 <i>Definition of Accounting Estimates</i>	1 January 2023
Amendments to MFRS 112 <i>Deferred Tax related to Assets and Liabilities arising from a Single Transaction</i>	1 January 2023
Amendments to MFRS 112 <i>International Tax Reform - Pillar Two Model Rules</i>	Refer MFRS112 Paragraph 98M
Amendment to MFRS 16 <i>Lease Liability in a Sale and Leaseback</i>	1 January 2024
Amendments to MFRS 101 <i>Classification of Liabilities as Current or Non-current</i>	1 January 2024
Amendments to MFRS 101 <i>Non-current Liabilities with Covenants</i>	1 January 2024
Amendments to MFRS 107 <i>Supplier Finance Arrangements</i>	1 January 2024
Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	Deferred

The Group and the Company are in the process of assessing the impact of implementing these Standards and Amendments to Standards, since the effects would only be observable for the future financial years.

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**A3. Auditors' Report**

There was no qualification on the audited financial statements of the Group for the financial year ended 31 July 2022.

**A4. Seasonal or Cyclical Factors**

The business operations of the Group were not affected by any seasonal or cyclical trend during the current quarter and financial year under review.

**A5. Material Unusual Items**

There were no unusual items affecting the assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial year under review.

**A6. Material Changes in Estimates**

There were no changes in estimates that have a material effect in the current quarter and financial year under review.

**A7. Debt and Equity Securities**

There was no issuance, cancellation, repurchase, resale and repayment of debts and equity securities during the current quarter and financial year under review.

**A8. Dividend Paid**

No dividend was paid during the current quarter.

**A9. Segmental Information**

The Group is principally involved in investment holding. Through its subsidiaries, the Group is principally involved in marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all its products. The Group is also involved in developing, manufacturing and marketing of its medical consumables.

For management purposes, the Group is organised into business units based on its products and services. The reportable segments of the Group are as follows:

(a) Marketing and distribution – marketing and distribution of medical devices as well as the provision of after-sales service; and

(b) Manufacturing – developing, manufacturing and marketing of medical consumables.

The Group's segmental information for the financial year under review is as follows:

<b>31 July 2023</b>	<b>Manufacturing</b>	<b>Marketing and distribution</b>	<b>Eliminations</b>	<b>Consolidated</b>
	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>
<b>Results</b>				
Revenue from external customers	14,955	30,477	-	45,432
Inter-segment revenue	957	-	(957)	-
Total revenue	<u>15,912</u>	<u>30,477</u>	<u>(957)</u>	<u>45,432</u>
Interest income and distribution income from short-term fund	53	358	-	411
Interest expense	(38)	(228)	13	(253)
Net Interest expense	<u>(15)</u>	<u>130</u>	<u>13</u>	<u>158</u>
Segment profit before tax	5,075	7,859	(2)	12,932



**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**A10. Material Events Subsequent to the end of the Quarter**

Save as disclosed in Note B6 on the Status of Corporate Proposals, there were no other material events subsequent to the end of the current quarter and financial year under review that have not been reflected in this interim financial report.

**A11. Changes in the Composition of the Group**

UMC had on 30 March 2023 completed the acquisition of 280,000 ordinary shares in Patho Solutions (M) Sdn Bhd ("**Patho**"), representing 70% equity interest in Patho, for a cash consideration of RM600,000 ("**Acquisition**").

On 31 March 2023, UMC subscribed an additional 700,000 new ordinary shares in Patho at an issue price of RM1.00 per share, for a cash consideration of RM700,000 ("**Subscription**").

Upon completion of the Acquisition and the Subscription, Patho is now a 70%-owned subsidiary of UMC.

Save for the above, there were no changes in the composition of the Group during the current quarter and financial year under review.

**A12. Contingent Liabilities and Contingent Assets**

There were no material contingent liabilities or contingent assets as at the date of this interim financial report.

**A13. Material Capital Commitment**

Save as disclosed below, as at 31 July 2023, the Group does not have any other material capital commitment:

	RM'000
Capital expenditure in respect of purchase of property, plant and equipment	
- Approved and contracted for	3,009
- Approved but not contracted for	7,170
<b>Total</b>	<b>10,179</b>

**A14. Significant Related Party Transactions**

There were no significant related party transactions during the current quarter.

**A15. Derivative Financial Instruments**

**Derivatives**

The Group has entered into forward foreign currency contracts with financial institutions due within 1 year to sell at contractual forward rates.

As at 31 July 2023, the Group's outstanding derivatives are as follow:

	Contract amount as at 31 July 2023		Fair value as at 31 July 2023
	USD'000	RM'000 equivalent	
Forward foreign currency contracts	180	816	810

**A16. Fair Value of Financial Instruments**

**Gains/(Losses) arising from Fair Value Changes of Financial Assets**

The Group recorded a gain from fair value changes of the forward foreign currency contracts approximately RM5,625 during the current quarter.

The fair value of a forward foreign currency contract is the amount that would be receivable upon termination of the outstanding position arising and is determined by reference to the difference between the contracted forward rate quoted by the financial institutions and the observable current market forward exchange rate as at the end of each reporting period.

The difference between the forward rates entered into, and the market rates, is recognised as derivatives asset or liability as applicable with a corresponding amount reported in the profit or loss.

**B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS**

**B1. Review of Performance**

**Comparison with the corresponding period/year in the previous financial period/year**

	Individual Quarter 3-months ended		Cumulative Quarter 12-months ended	
	31 July 2023 (RM'000)	31 July 2022 (RM'000)	31 July 2023 (RM'000)	31 July 2022 (RM'000)
Revenue	12,015	7,411	45,432	50,738
Profit before tax ("PBT")	4,499	304	12,932	8,482
Profit for the financial period/year	3,407	568	10,364	6,426
Profit attributable to owners of the parent	3,371	568	10,316	6,426

The Group's revenue increased by approximately RM4.60 million or 62.12% from approximately RM7.41 million achieved in the corresponding quarter of the previous financial period to approximately RM12.02 million in the current quarter. However, the Group's revenue decreased by approximately RM5.31 million or 10.46% from approximately RM50.74 million achieved in the previous financial year to approximately RM45.43 million in the current financial year.

The PBT of the Group increased by approximately RM4.20 million or 1379.93% from approximately RM0.30 million in the corresponding quarter of the previous financial year to approximately RM4.50 million in the current quarter. The PBT of the Group also increased by approximately RM4.45 million or 52.46% from approximately RM8.48 million in the previous financial year to approximately RM12.93 million in the current financial year.

The increase in revenue and PBT in the current quarter as compared to the corresponding quarter was contributed by both the marketing and distribution and manufacturing segments. The increase was mainly due to a higher demand for medical devices and consumables from both public and private hospitals as well as healthcare service providers. In addition, the increase in the Group's revenue was also contributed by the increase in the sale of its manufactured medical consumables, namely HydroX series prefilled humidifiers and AirdroX series inhaler spacers, with a better foreign exchange rate for overseas revenue.

**B2. Comparison with Immediate Preceding Quarter**

	Individual Quarter 3-months ended			
	31 July 2023 (RM'000)	30 April 2023 (RM'000)	Differences	
			RM'000	%
Revenue	12,015	9,585	2,430	25.35
PBT	4,499	2,460	2,039	82.89
Profit for the financial period	3,407	2,047	1,360	66.44
Profit attributable to owners of the parent	3,371	2,035	1,336	65.65

The Group's revenue increase by approximately RM2.43 million or 25.35% from approximately RM9.59 million achieved in the immediate preceding quarter to approximately RM12.02 million for current quarter. The increase in revenue was mainly derived from the increase orders from marketing and distribution segment.

In view of the increase in revenue, the Group's PBT also increased by approximately RM2.04 million or 82.89% from approximately RM2.46 million achieved in the immediate preceding quarter to approximately RM4.50 million in the current quarter.

**B3. Prospects**

Aligned with the Malaysian government's emphasis and commitment towards improving the nation's quality of healthcare, the Group maintains a positive outlook on its future. This is premised on several growth drivers, which include the rapidly growing and ageing population as well as medical tourism, which in turn increases the need to upgrade existing medical devices and establish new healthcare facilities.

The Ministry of Health has allocated RM36.3 billion under Budget 2023 which represents a 12.0%, or RM3.9 billion increase against the previous year's allocation of RM32.4 billion, and this is the second highest budget allocation which attests to the government's continued emphasis on the healthcare sector. This augurs well for UMC as this will further elevate demand for its medical devices over the coming financial periods.

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**B3. Prospects (cont'd)**

Moreover, BMI Research also suggests that the nation's healthcare expenditure for both public and private hospitals are expected to trend steadily upwards going into year 2027. BMI Research has projected a 5-year compound annual growth rate of 8.0% and 7.3% for the public and private healthcare expenditure respectively, which will bolster the demand in the medium term. This projection when paired with UMC's recent strategic acquisition of Patho Solutions (M) Sdn Bhd, bodes well for the Group and will allow the Group to tap into the laboratory segments by leveraging on its existing strong distribution networks and presence to cater to a wider market within the medical industry.

Given the ample opportunities ahead, the Group remains confident of its future growth trajectory.

**B4. Profit Forecast**

The Group did not issue any profit estimate, forecast, projection or internal targets in any public document.

**B5. Taxation**

The Group's taxation together with the comparison between the effective and statutory tax rates for the current quarter and financial year under review are as follows:

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	3-month ended 31 July 2023 RM'000	3-month ended 31 July 2022 RM'000	12-month ended 31 July 2023 RM'000	12-month ended 31 July 2022 RM'000
<b>Income tax</b>				
Current tax expenses based on profit for the financial period/year	643	287	1,870	2,482
Under/(over)provision of tax expense in prior year	9	(10)	(37)	132
<b>Deferred tax</b>				
Relating to origination and reversal of temporary differences	440	(547)	735	(672)
Under/(over)provision in prior years <sup>(a)</sup>	*	6	*	114
Overall tax expenses	1,092	(264)	2,568	2,056
Effective tax rate (%)	24.27	(86.84)	19.86	24.24
Statutory tax rate (%)	24.00	24.00	24.00	24.00

**Note:**

\* Represent less than RM1,000.

(a) There is an overprovision deferred tax in prior year amounting to RM615 during the current financial year.

The Group's effective tax rate was at 19.86% for current financial year. The effective tax rate for current financial year was lower than the statutory tax rate of 24.00% mainly due to the following:

- (i) tax incentive enjoyed by its wholly-owned subsidiary, UWHM Sdn Bhd. UWHM Sdn Bhd is entitled to reinvestment allowance incentives under Schedule 7A, Income Tax Act 1967 for qualifying capital expenditure on the acquisition of machinery and equipment;
- (ii) amortisation of grants, which was not subject to income tax and,
- (iii) Patho enjoyed SME preferential tax rate of 15% for the first RM600,000 of chargeable income for current year of assessment.

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**B6. Status of Corporate Proposals**

There were no corporate proposals announced and not completed as at the date of this interim financial report.

**B7. Utilisation of Proceeds from the Initial Public Offering (“IPO”)**

The gross proceeds from the IPO amounting to RM31.11 million is expected to be utilised in the following manner:

Details of the use of proceeds	Estimated timeframe for the use of proceeds upon listing <sup>(1)</sup>	Proposed Utilisation RM'000	Actual Utilisation RM'000	Percentage utilised %	Deviation	
					RM'000	%
Capital expenditure						
(i) Construction of new factory building	Within thirty (30) months	3,500	2,381	68.03	-	-
(ii) Setting up new marketing and distribution offices	Within thirty-six (36) months	6,800	-	-	-	-
		10,300	2,381	23.12	-	-
Repayment of bank borrowings <sup>(2)</sup>	Within six (6) months	9,000	9,000	100.00	-	-
Working capital	Within thirty-six (36) months	8,662	8,662	100.00	-	-
Estimated listing expenses	Within two (2) months	3,150	3,150	100.00	-	-
<b>Total</b>		<b>31,112</b>	<b>23,193</b>			

**Notes:**

- (1) From the date of listing of the Company on the ACE Market of Bursa Securities on 26 July 2022.  
(2) Including lease liabilities owing to financial institutions.

**B8. Group Borrowings and Debt Securities**

The details of the Group's borrowings are as follows:

	12-month ended 31 July 2023 RM'000	Audited as at 31 July 2022 RM'000
<b>Current liabilities</b>		
Term loan	711	962
Bankers' acceptance	-	1,450
	<b>711</b>	<b>2,412</b>
<b>Non-current liabilities</b>		
Term loan	2,877	5,584
	<b>2,877</b>	<b>5,584</b>
<b>Total borrowings</b>	<b>3,588</b>	<b>7,996</b>

All the Group's borrowings are denominated in RM, secured and interest-bearing.

**B9. Material Litigation**

As at the date of this interim financial report, the Group is not engaged in any material litigation or arbitration proceedings, either as plaintiff or defendant, and the Directors are not aware of any proceedings pending or threatened against the Group, which may materially and adversely affect the financial position or business performance of the Group.

**B10. Dividend**

No dividend has been declared or recommended for the current quarter ended 31 July 2023.

**B11. Earnings Per Share**

The basic and diluted EPS for the current quarter and financial year are computed as follows:

	<b>3-month ended 31 July 2023</b>	<b>3-month ended 31 July 2022</b>	<b>12-month ended 31 July 2023</b>	<b>12-month ended 31 July 2022</b>
Profit attributable to the owners of the parent (RM'000)	3,371	568	10,316	6,426
Number of ordinary shares (unit) ('000)	373,910	373,910	373,910	373,910
Basic EPS <sup>(1)</sup> (sen)	0.90	0.15	2.76	1.72
Diluted EPS <sup>(2)</sup> (sen)	0.90	0.15	2.76	1.72

**Notes:**

- (1) Basic EPS is calculated by dividing the profit attributable to owners of the parent by the number of ordinary shares outstanding during the financial period/year under review.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period/year under review.

(The remaining of this page is intentionally left blank)

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**B.12 Profit Before Tax**

Profit before tax is arrived at after charging/(crediting):

	<b>12-month ended 31 July 2023</b>	<b>12-month ended 31 July 2022</b>
	<b>RM'000</b>	<b>RM'000</b>
Depreciation of property, plant and equipment	2,048	1,529
Depreciation of right-of-use assets	138	218
Fair value adjustment on derivative assets	(6)	-
Amortisation of government grants	(370)	(87)
Finance costs	253	807
Gain on disposal of property, plant and equipment	-	(2)
Gain on lease terminations <sup>(1)</sup>	*	*
Interest income	(108)	(116)
Distribution income from short-term fund	(303)	(1)
Property, plant and equipment written off	2	-
Realised gain on fair value adjustment on marketable securities	(268)	(6)
Reversal of impairment losses on trade receivables	(12)	(14)
Unrealised loss/(gain) on foreign exchange	142	(9)

**Notes:**

\* Represent less than RM1,000.

(1) There is a gain on lease terminations amounting to RM251 during the current financial year and RM368 for financial year ended 31 July 2022.

Save as disclosed above, the other disclosure items pursuant to Note 16, of Appendix 9B of the Listing Requirements are not applicable.

**BY ORDER OF THE BOARD**  
**12 September 2023**